Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes

Introduction: Degludec (IDeg) is an ultralong-acting insulin, with stable pharmacodynamic profile which leads to lower fluctuations in glucose levels. The effect of IDeg has not been specifically assessed in patients with unstable diabetes, defined as increased glycemic variability (GV). Methods: A...

Full description

Bibliographic Details
Main Authors:	Diana Cristina Henao-Carrillo, Oscar M. Muñoz, Ana M. Gómez, Martín Rondón, Christian Colón, L. Chica, Claudia Rubio, Fabián León-Vargas, Maria Alejandra Calvachi, Ana María Perea
Format:	Article
Language:	English
Published:	Elsevier 2018-06-01
Series:	Journal of Clinical & Translational Endocrinology
Subjects:	Type 1 diabetes Type 2 diabetes Glycemic variability Insulin degludec
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214623718300206

Similar Items

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-06-01)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
by: Minze MG, et al.
Published: (2016-03-01)

Insulin degludec aspart: One-year real world experience
by: Sanjay Kalra, et al.
Published: (2016-01-01)

THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT
by: M. F. Kalashnikova, et al.
Published: (2016-12-01)

Degludec insulin: A novel basal insulin
by: Sanjay Kalra, et al.
Published: (2011-01-01)

Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes
by: Debmalya Sanyal, et al.
Published: (2021-03-01)

Use of insulin degludec in pregnancy: two case reports and a literature review
by: E. Sprio, et al.
Published: (2020-11-01)

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes
by: Barbara Predieri, et al.
Published: (2018-08-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
by: Han Na Jang, et al.
Published: (2019-12-01)

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015-11-01)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
by: Sarah J. Glastras, et al.
Published: (2020-04-01)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
by: Mitsuhisa Komatsu, et al.
Published: (2021-09-01)

Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study
by: Kanta Fujimoto, et al.
Published: (2018-08-01)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
by: Sanjay Kalra
Published: (2016-01-01)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
by: Tevfik Demir, et al.
Published: (2021-03-01)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
by: Richard E. Pratley, et al.
Published: (2019-11-01)

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability
by: Valentina Guarnotta, et al.
Published: (2018-07-01)

A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus
by: A. S. Pogorelova
Published: (2018-07-01)

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design
by: Rikke Mette Agesen, et al.
Published: (2019-07-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation
by: James Weatherall, et al.
Published: (2018-05-01)

The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus – outcomes from cross‐over open-label randomized trial
by: Pavle Vrebalov Cindro, et al.
Published: (2021-04-01)

Modern basal insulin analogs: An incomplete story
by: Awadhesh Kumar Singh, et al.
Published: (2014-01-01)

Concentrated insulins: the new basal insulins
by: Lamos EM, et al.
Published: (2016-03-01)

Future of newer basal insulin
by: S V Madhu, et al.
Published: (2013-01-01)

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study
by: Stefano Tumini, et al.
Published: (2020-04-01)

Clinically Relevant Insulin Degludec and Its Interaction with Polysaccharides: A Biophysical Examination
by: Shahwar Imran Jiwani, et al.
Published: (2020-02-01)

Depressive symptoms in Type 1 and Type 2 Diabetes Mellitus and its relationship with glycemic control
by: Ilda Maria Massano-Cardoso, et al.
Published: (2020-05-01)

The Effect of Basal Analog Insulin on the Glycemic Variability in Type 2 Diabetics
by: Soner Cander, et al.
Published: (2014-06-01)

New strategies of insulin therapy - a way to effective glycemic control of type 2 diabetes mellitus
by: Elena Valer'evna Biryukova
Published: (2009-12-01)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017-04-01)

Study of factors associated with poor glycemic control in Type -2 Diabetic patients
by: Prabhakara K, et al.
Published: (2013-05-01)

Effect of celiac disease on glycemic control among subjects with autoimmune insulin-dependent diabetes
by: Aldoukhi, Ali
Published: (2016)

Better Glycemic Control with Insulin Premix 50/50 TID Compared to Insulin Premix 70/30 BID - Original Article
by: Hasan Aydın, et al.
Published: (2010-09-01)

Flexibility in insulin prescription
by: Sanjay Kalra, et al.
Published: (2016-01-01)